Tablet Coating Defects in Pharmaceutical Manufacturing: Causes and Polymer Solutions

Every tablet that reaches a patient has passed through one of the most technically demanding stages in pharmaceutical manufacturing: coating. What appears to be a simple protective shell is a precisely engineered polymer film that governs drug release, shelf-life stability, and patient compliance.

At Vikram Thermo, we’ve spent over 40 years helping manufacturers prevent tablet coating defects through intelligent polymer selection and formulation support. This guide reflects insights from thousands of development projects, regulatory filings, and commercial manufacturing campaigns across 45+ countries.

Tablet coating defects are among the most common causes of batch failure in solid dosage manufacturing and among the most preventable when formulation teams understand the polymer fundamentals.

 

Download Vikram Thermo’s trouble shooting guide for tablet coatings

 

WHAT ARE TABLET COATING DEFECTS?

Tablet coating defects are undesirable physical, functional or aesthetic imperfections that develop during or after the film coating process, compromising drug quality, stability and regulatory acceptability.

The more dangerous category is functional defects: altered dissolution profiles, failed moisture barriers and dose dumping in extended-release systems. These are invisible to the naked eye, can pass initial release testing and only surface during stability studies or post-launch.

Defects arise from three sources: formulation gaps (wrong polymer, wrong plasticiser and incorrect viscosity), process deviations (spray rate, temperature and pan speed) and tablet core variability (porosity, hardness, surface roughness). Of these, the polymer is the highest-leverage control point; it determines how the coating behaves under every other condition in the process.

This is why our approach begins with polymer selection, not process troubleshooting.

TYPES OF TABLET COATING DEFECTS

Mechanical Defects

Cracking, chipping, peeling and capping indicate insufficient film strength or poor adhesion. The cause is almost always a polymer that is too brittle; either the molecular weight is incorrect or the plasticiser concentration is too low to bring the glass transition temperature (Tg) to a workable range. Cracking is especially prevalent in enteric-coated tablets, where the film must resist acidic conditions while withstanding mechanical stress during pan rotation and handling.

Visual Defects

Orange peel, mottling, streaking and blushing frequently signal deeper formulation issues. Orange peel occurs when spray droplets dry before spreading and coalescing on the tablet surface, a direct result of mismatched polymer viscosity and atomisation conditions. Mottling reflects poor pigment dispersion, pointing to inadequate suspension homogenisation or polymer-colourant incompatibility.

Process-Induced Defects

Sticking, picking and twinning are driven by process conditions but strongly amplified by polymer selection. Sticking tablets, adhering to each other or the pan wall, is the most frequently reported defect in aqueous film coating. It occurs when the film surface remains tacky, either from insufficient drying or a polymer Tg too low for the process temperature.

Functional Defects

These carry the most clinical significance. Pinhole formation in extended-release coatings causes dose dumping, defined as the release of more than 40% of the labelled dose within the first hour, a direct patient safety risk for narrow therapeutic index drugs. Enteric coating failures cause premature gastric drug release. Moisture barrier failures accelerate API degradation. These defects demand formulation-level solutions, not process corrections alone.

HOW TABLET COATING WORKS: THE MECHANISM

Understanding how tablet coating works is essential to preventing defects. The coating solution, comprising polymer, plasticiser, solvent or water, pigment, and process aids, is atomised into fine droplets onto a rotating tablet bed. Droplets too fine dry before reaching the surface, arriving as discrete particles that cannot coalesce, producing orange peel. Droplets that are too coarse deposit excess liquid, causing over-wetting and sticking.

Once deposited, droplets must spread, coalesce, and dry in a controlled sequence, governed by the polymer’s Minimum Film Forming Temperature (MFFT). If the tablet surface temperature falls below the In MFFT, polymer particles remain discrete, forming a weak, porous film prone to cracking and moisture penetration.

Plasticisers control the MFFT by lowering the polymer’s Tg. Too little plasticiser and the film cracks. Too much and it stays tacky, causing sticking. Getting this balance right is the mechanism by which the entire film formation process is enabled.

For extended-release systems using water-insoluble methacrylic copolymers such as our DRUGCOAT® RL and RS series, a mandatory post-coating curing step typically at 40-60°C for 12-24 hours ensures complete polymer coalescence into a stable membrane. Without curing, the matrix continues to densify during storage, causing progressive release rate drift that can render a product out of specification within months.

This is why our formulations specify mandatory curing protocols and provide stability data supporting them across multiple climatic zones.

APPLICATIONS: WHERE POLYMER SELECTION IS CRITICAL

Immediate Release (IR) Coatings

Serve protective and cosmetic functions: moisture barrier, taste masking, and identification. The polymer must dissolve rapidly while providing adequate mechanical protection. Our DRCOAT® FCA, FCA II, and FCA III are HPMC-based aqueous systems designed for this application, while DRCOAT® HSP offers a PVA-based aqueous alternative for formulations requiring superior moisture resistance at the IR stage.

Enteric Coatings

Use pH-responsive methacrylic acid copolymers that remain intact in gastric conditions. Our DRUGCOAT® L30D and L100-55 dissolve above pH 5.5, making them the standard choice for small intestine-targeted delivery. The enteric coating polymer selection is critical for ensuring the drug reaches its intended site. DRUGCOAT® L100 dissolves above pH 6.0 for non-aqueous processing, while DRUGCOAT® S100 targets colon-specific delivery, dissolving above pH 7.0, an important distinction for APIs requiring distal intestinal release. On the ready-to-use side, DRCOAT® ECA handles aqueous enteric applications, DRCOAT® ECS is suited for non-aqueous processing, and DRCOAT® EZ is a ready-to-spray aqueous dispersion for streamlined production.

Sustained and Controlled Release Coatings

Use semi-permeable membranes to control drug diffusion. Understanding the distinction between immediate vs sustained release is fundamental to formulation success. Our DRUGCOAT® RL series (Ammonio Methacrylate Copolymer, Type A) provides pH-independent swelling with higher permeability, while the DRUGCOAT® RS series (Type B) offers more restricted drug permeation for tighter release control. DRUGCOAT® NE 30D, an aqueous dispersion of ethyl acrylate and methyl methacrylate copolymer, provides an alternative aqueous sustained-release membrane system. A single membrane defect in any of these is sufficient to cause dose dumping.

Moisture Barrier Coatings

Protect hygroscopic APIs throughout storage. Selecting the right film coating polymer for tablets determines barrier effectiveness. Our DRCOAT® MB-A and DRCOAT® HSP+ serve aqueous processing environments, while DRCOAT® MB-S handles solvent-based requirements. Achieving target water vapour transmission rates requires both the right polymer system and adequate coat weight gain, typically 3-5%.

Taste Masking

Addressed by our DRUGCOAT® E series gastric-soluble amino methacrylate copolymers that dissolve below pH 5.0, masking bitterness in the mouth while releasing the API rapidly in the stomach. Our taste-masking coating polymer approach ensures patient compliance and palatability. Available as granules (E100), powder (EPO), or organic solution (E12.5) to suit different processing configurations.

COMPARISON TABLE: DEFECTS, CAUSES, AND POLYMER-BASED SOLUTIONS

TROUBLESHOOTING: KEY CHALLENGES

Process sensitivity compounds quickly; small deviations in spray rate, temperature, or pan speed translate directly into visible defects. Our approach is to build a robust process window during development based on thorough understanding of the polymer’s processing characteristics before production begins.

Tablet core variability is underappreciated as a defect driver. High-porosity cores absorb coating solution unevenly; friable edges trap and crack coating material. We recommend addressing these at the core formulation stage rather than compensating through coating parameters. Where core porosity is unavoidable, a seal coat such as our DRCOAT® SEAL, applied and fully dried before the functional coating layer, significantly reduces blistering risk.

A polymer-process mismatch is the most correctable root cause. A polymer designed for non-aqueous systems behaves unpredictably in an aqueous process. Our ready-to-use systems such as DRCOAT® eliminate this by pre-characterising formulation performance, viscosity profile, film strength and dissolution behaviour across a defined process window before the product reaches you.

Environmental conditions, particularly high ambient humidity in tropical manufacturing sites, slow evaporation and extend the window during which the film is tacky. Our polymer systems with faster film formation rates provide a practical buffer, a directly relevant consideration for pharmaceutical coating polymers used across South and Southeast Asian manufacturing environments.

HOW POLYMER SELECTION PREVENTS COATING DEFECTS

The connection is direct and mechanistic. A polymer with the correct molecular weight delivers the right coating viscosity at a practical solids concentration. A polymer with appropriate Tg, correctly plasticised, forms a continuous film at process temperatures without remaining tacky. A pH-responsive polymer selected for the correct dissolution threshold releases where it should and nowhere else.

Modern QbD practice under ICH Q8 treats polymer specification as a critical material attribute defined, validated, and controlled across the product lifecycle. Changing a polymer grade post-approval is a regulatory event requiring substantial justification. Getting the selection right in development is both sound science and sound regulatory strategy.

Our ready-to-use systems such as DRCOAT® carry this logic further. By pre-combining polymer, plasticiser, pigment, and process aids in optimised ratios with options spanning HPMC-based, PVA-based, methacrylic acid-based and MICA-based systems, we eliminate formulation variability from in-house blending and convert critical polymer properties into known quantities rather than production variables.

INDUSTRY PLAYERS AND COMPETITIVE POSITIONING

The pharmaceutical coating polymer market includes several established suppliers, each with distinct technical capabilities and market positioning.

Evonik Industries (Germany)

Colorcon (USA)

BASF (Germany)

VIKRAM THERMO’S TECHNICAL CAPABILITY

We are world second largest methacrylic acid manufacturers, operating across the complete pharmaceutical coating polymer spectrum. Our DRUGCOAT® portfolio spans enteric (L/S series, pH 5.5–7.0), sustained-release (RL/RS/NE series), and gastric-soluble (E series) applications. Our DRCOAT® ready-to-use systems cover immediate release, enteric, moisture barrier, and speciality segments, matching competitor breadth across both traditional and preformulated platforms.

Regulatory Standing

We maintain EXCiPACT GMP certification, US DMF registration, ISO 9001, WHO cGMP, and HALAL certifications, an identical regulatory standing to premium suppliers. Our manufacturing facilities in India deliver equivalent technical performance without geographic concentration risk.

Technical Support

Our approach emphasises formulation partnership from development through commercial scale. Process window characterisation, stability data across climatic zones, mandatory curing protocols, and regulatory support are standard services, not premium add-ons.

Supply Chain Resilience

Our multi-facility manufacturing approach and global distribution partnerships across 45+ countries provide supply continuity that single-facility competitors cannot match. This resilience is particularly relevant for manufacturers requiring consistent polymer supply across multiple manufacturing sites.

This positioning allows manufacturers to evaluate suppliers based on total technical capability and partnership value, not brand recognition or geographic proximity alone.

FAQs

1. What is the most common tablet coating defect?

Sticking and picking are most prevalent in aqueous systems. It occurs when the film remains tacky due to insufficient drying or a polymer Tg too low for process conditions. Primary corrections are increasing inlet temperature, reducing spray rate, and implementing a mandatory post-coating curing step for RL/RS-based systems.

2. How does polymer selection prevent tablet coating defects and solutions?

Polymer selection governs Tg, MFFT, tensile strength, adhesion, and dissolution behaviour. A correctly matched pharmaceutical coating polymer eliminates the root cause of most defect categories. Process adjustments alone cannot fully compensate for a mismatched polymer. This is why we begin every formulation project with polymer selection, not process troubleshooting.

3. Why does cracking occur specifically in enteric coatings?

Enteric polymers form stiffer films due to pH-resistance requirements. Insufficient plasticiser creates internal film stress exceeding tensile strength, producing cracks that become direct pathways for gastric fluid. Free-film tensile strength testing is the standard method for establishing the minimum effective plasticiser concentration. Our DRUGCOAT® L-series formulations specify plasticiser concentrations validated through this testing.

4. What is a ready-to-use coating system, and why does it reduce defect risk?

A pre-formulated blend of polymer, plasticiser, pigment, and process aids requiring only dilution before use. By pre-optimising critical polymer properties, systems like DRCOAT® eliminate batch-to-batch variability from in-house compounding, directly reducing defect rates across manufacturing sites. Our systems are validated across equipment types before supply.

5. Can coating defects affect patient safety?

Yes. ER membrane defects cause dose dumping. Enteric failures expose acid-labile APIs to gastric destruction. Moisture barrier failures accelerate API degradation. These are clinical consequences with direct therapeutic impact, not manufacturing inconveniences. This is why we specify mandatory curing protocols and provide comprehensive validation data for regulatory filings.

6. What role does QbD play in defect prevention?

QbD under ICH Q8 defines ‘polymer specification’ as a ‘critical material attribute’ within a validated design space, replacing reactive troubleshooting with proactive formulation design, identifying defect-causing conditions in development rather than during production or post-launch. Our development approach is built on QbD principles from initiation.

CONCLUSION

Tablet coating defects are predictable, mechanistically understood failures, not random manufacturing events. They trace directly to formulation decisions and most often to the polymer.

A coating that cracks, peels, sticks, or fails its release specification is built on the wrong polymer foundation. No process adjustment fully compensates for that mismatch. When the polymer system is correctly selected and characterised before the first production batch, tablet coating defects and solutions become problems solved on paper rather than failures discovered in the pan.

At Vikram Thermo, this approach has guided our formulation partnerships across 40+ years and 45+ countries. We provide the technical range, regulatory documentation and formulation support to match the right system to the right application from the sample stage through commercial scale.

 

Order your sample of an excipient product by Vikram Thermo India Ltd.

 

 

Excipients insights. Straight to your inbox. Subscribe now.